Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin-Reference-Cited by-同舟云学术

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin

Published:2016 Issue:3 Volume:40 Page:230
ISSN:2233-6079
Container-title:Diabetes & Metabolism Journal
language:en
Short-container-title:Diabetes Metab J

Author:

Kim Jong Ho¹,Kim Sang Soo¹,Baek Hong Sun²,Lee In Kyu³,Chung Dong Jin⁴,Sohn Ho Sang⁵,Bae Hak Yeon⁶,Kim Mi Kyung⁷,Park Jeong Hyun⁸,Choi Young Sik⁹,Kim Young Il¹⁰,Hahm Jong Ryeal¹¹,Lee Chang Won¹²,Jo Sung Rae¹³,Park Mi Kyung¹⁴,Lee Kwang Jae¹⁵,Kim In Joo¹^ORCID

Affiliation:

1. Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

2. Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea.

3. Department of Internal Medicine, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea.

4. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.

5. Department of Internal Medicine, Daegu Catholic University Medical Center, Catholic University of Daegu School of Medicine, Daegu, Korea.

6. Department of Internal Medicine, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Korea.

7. Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.

8. Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

9. Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.

10. Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.

11. Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.

12. Department of Internal Medicine, Busan St. Mary's Hospital, Catholic University of Pusan, Busan, Korea.

13. Department of Internal Medicine, Changwon Fatima Hospital, Changwon, Korea.

14. Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea.

15. Department of Internal Medicine, Daedong Hospital, Busan, Korea.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Korean Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism

Link

http://synapse.koreamed.org/pdf/10.4093/dmj.2016.40.3.230

Reference28 articles.

1. Global estimates of diabetes prevalence for 2013 and projections for 2035

2. The Epidemiology of Diabetes in Korea

3. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

4. Glitazones: clinical effects and molecular mechanisms

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-07

2. A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study;Diabetes, Obesity and Metabolism;2022-06-09

3. Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial;Diabetes, Obesity and Metabolism;2021-12-27

4. The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort;Frontiers in Genetics;2021-06-11

5. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials;Diabetes & Metabolism;2020-06